SEC Tracker
Get the app
CARM · As filed with the SEC

Carisma Therapeutics balance sheet, by fiscal year

The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousandsFY2024
Dec 31, 2024		FY2023
Dec 31, 2023		FY2022
Dec 31, 2022		FY2021
Dec 31, 2021
Assets
Current assets:
Cash and cash equivalents17,90977,605112,553162,636
Marketable securities—054,366—
Restricted cash——21,0000
Accounts receivables——021,011
Other receivables——8253,482
Prepaid expenses and other assets5,9162,86640018,476
Total current assets23,82580,471189,144205,605
Restricted cash——3020
Property and equipment, net——043
Intangible assets——014,700
Goodwill——013,064
Long term prepaid expenses——07,192
Other assets——0123
Total non-current assets——3035,142
Property and equipment, net4,3856,764——
Right of use assets – operating leases2,0402,173——
Deferred financing costs—146——
Deferred financing costs208———
Total assets30,45889,554189,174240,747
Liabilities and Stockholders' (Deficit) Equity
Current liabilities:
Accounts payable2,0813,9331,2332,853
Accrued expenses7,4487,66229,6368,255
Deferred revenue———0
Contingent consideration———0
Deferred revenue3,7291,413——
Operating lease liabilities8321,391——
Finance lease liabilities905544——
Other current liabilities1,060965115460
Total current liabilities16,05515,90830,98411,568
Contingent consideration——052,000
Deferred tax liability——03,969
Deferred revenue——01,500
Total non-current liabilities——057,469
Deferred revenue41,25045,000——
Convertible promissory note—0——
Derivative liability—0——
Operating lease liabilities724860——
Finance lease liabilities20328——
Other long-term liabilities318926—0
Total liabilities58,36763,02230,98469,037
Convertible preferred stock—0——
Stockholders’ (deficit) equity:
Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding0000
Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December 31, 2024 and 2023, respectively4140202199
Additional paid-in capital277,629271,594494,675487,768
Accumulated other comprehensive loss—0(546)—
Accumulated deficit(305,579)(245,102)(336,141)(316,257)
Total Carisma Therapeutics Inc. stockholders’ equity (deficit)—26,532158,190171,710
Noncontrolling interests—0——
Total stockholders’ (deficit) equity(27,909)26,532——
Total liabilities and stockholders’ (deficit) equity30,45889,554189,174240,747

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.